When attendees gathered last year, riding the wave of expected post-COVID increases in demand, funding, and utilization, addiction treatment mergers and acquisitions were at unprecedented levels—but will this last? In this session, tapping into proprietary data compiled by The Braff Group, the panelists will take a deep dive into the who, what, why, and how much of substance use disorder M&A. Have the gains made in mid-range to value residential programs continued? Has deal volume in outpatient PHP/IOP and other community-based programs finally caught up with trends favoring outpatient services? Are there new healthcare policy initiatives influencing acquisition strategies? They will cover these questions and more in this state-of-the-industry presentation.